Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221032 · ClinicalTrials.gov registry record · Phase 1
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07221032 is a Phase 1 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 12 participants.
The verdict
NCT07221032, a Phase 1 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
Interventions
- BIOLOGICAL FT836 CAR T cells (1 x 10^8 cells per dose)
- BIOLOGICAL FT836 CAR T cells (3 x 108 cells per dose)
- BIOLOGICAL FT836 CAR T cells (up to 9 x 108 cells per dose)
- DRUG Daratumumab 16 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221032
The ClinicalTrials.gov registry entry for NCT07221032 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FT836 CAR T cells (1 x 10^8 cells per dose) is the first listed.
NCT07221032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221032 about?
NCT07221032 is a clinical study titled "FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma". This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
What is the current status of trial NCT07221032?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-07. Estimated completion is 2030-03.
What interventions are being tested in trial NCT07221032?
The interventions under investigation include: FT836 CAR T cells (1 x 10^8 cells per dose) (BIOLOGICAL), FT836 CAR T cells (3 x 108 cells per dose) (BIOLOGICAL), FT836 CAR T cells (up to 9 x 108 cells per dose) (BIOLOGICAL), Daratumumab 16 mg/kg (DRUG).
Who is sponsoring clinical trial NCT07221032?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.